Search

Your search keyword '"D’Hondt, Véronique"' showing total 159 results
Start Over Author "D’Hondt, Véronique"
159 results on '"D’Hondt, Véronique"'

1. Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial

Author

Ginzac, Angeline, Molnar, Ioana, Durando, Xavier, Motte Rouge, Thibault De La, Petit, Thierry, D’hondt, Véronique, Campone, Mario, Bonichon-Lamichhane, Nathalie, Venat Bouvet, Laurence, Levy, Christelle, Augereau, Paule, Pistilli, Barbara, Arsene, Olivier, Jouannaud, Christelle, Nguyen, Suzanne, Cayre, Anne, Tixier, Lucie, Mahier Ait Oukhatar, Céline, Nabholtz, Jean-Marc, Penault-Llorca, Frédérique, and Mouret-Reynier, Marie-Ange

Published
2024
Full Text
View/download PDF

2. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Author

Abadie-Lacourtoisie, Sophie, Andreetta, Claudia, Anzizar, Nerea, Aoki, Daiseuke, Barretina-Ginesta, Maria-Pilar, Battista, Marco, Bellier, Charlotte, Bentzen, Anne Gry, Berton, Dominique, Billemont, Bertrand, Bjørge, Line, Bjurberg, Maria, Black, Destin, Bologna, Alessandra, Braicu, Elena Ioana, Casanova, Claudia, Chekerov, Radoslav, Chevalier, Annick, Cueva, Juan Fernando, Czogalla, Bastian, Delanoy, Nicolas, Denschlag, Dominik, Derke, Oscar, Eichbaum, Michael, Enomoto, Takayuki, Esteban, Carmen, Fabbro, Michel, Fehm, Tanja, Ferrero, Annamaria, Fleisch, Markus, Floquet, Anne, Frassoldati, Antonio, Gaba, Lydia, Gadducci, Angiolo, García, Yolanda, Geuna, Elena, Guerra, Eva, Hanker, Lars, Hardy-Bessard, Anne-Claire, Harter, Philipp, Hasegawa, Kosei, Hellman, Kristina, Herrero, Ana, Hilpert, Felix, Katsaros, Dionyssios, Koegel, Matthias, Koliadi, Anthoula, Kurtz, Jean-Emmanuel, Lampe, Bjoern, Lissoni, Andrea Alberto, Lortholary, Alain, Mangili, Giorgia, Mansi, Laura, Marmé, Frederik, Mathews, Cara, Mina, William, Minobe, Shinichiro, Moxley, Katherine, Nagao, Shoji, Nicoletto, Ornella, Nishino, Koji, Nishio, Hiroshi, Nishio, Shin, Oaknin, Ana, Onstad, Michaela, Pardo, Beatriz, Pérez-Fidalgo, J Alejandro, Pisano, Carmela, Poveda, Andrés, Radosa, Julia, Randall, Leslie M., Ray-Coquard, Isabelle, Redondo, Andrés, Richardson, Debra, Romero, Ignacio, Ronzino, Graziana, Rubio, Maria Jesús, Selle, Frederic, Takekuma, Munetaka, Takeshima, Nobuhiro, Tasca, Giulia, Tewari, Krishnansu, Todo, Yukiharu, Valabrega, Giorgio, Wimberger, Pauline, Woelber, Linn, Yamaguchi, Satoshi, You, Benoît, Yunokawa, Mayu, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, De Giorgi, Ugo, Lindemann, Kristina, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Angelergues, Antoine, Fariñas-Madrid, Lorena, Lorusso, Domenica, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Lebreton, Coriolan, Dahlstrand, Hanna, D'Hondt, Véronique, and Randall, Leslie M

Published
2024
Full Text
View/download PDF

3. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

Author

BIDARD, Francois-Clement, PISTILLI, Barbara, DALENC, Florence, BACHELOT, Thomas, DE LA MOTTE ROUGE, Thibault, SABATIER, Renaud, DUBOT, Coraline, FRENEL, Jean-Sébastien, FERRERO, Jean-Marc, LADOIRE, Sylvain, LEVY, Christelle, MOURET-REYNIER, Marie-Ange, HARDY-BESSARD, Anne-Claire, LORTHOLARY, Alain, GRENIER, Julien, CHAKIBA, Camille, STEFANI, Laetitia, SOULIE, Patrick, JACQUIN, Jean-Philippe, PLAZA, Jérôme Edouard, CLATOT, Florian, TEIXEIRA, Luis, D'HONDT, Véronique, VEGAS, Hélène, DERBEL, Olfa, GARNIER TIXIDRE, Claire, DELBALDO, Catherine, MOREAU, Lionel, CHENEAU, Caroline, PAITEL, Jean-François, BERNARD-MARTY, Chantal, SPAETH, Dominique, GENET, Dominique, MOULLET, Isabelle, BONICHON-LAMICHHANE, Nathalie, DEIANA, Laura, GREILSAMER, Charlotte, VENAT-BOUVET, Laurence, DELECROIX, Valérie, MELIS, Adrien, ORFEUVRE, Hubert, NGUYEN, Suzanne, LEGOUFFE, Eric, ZANNETTI, Alain, LE SCODAN, Romuald, DOHOLLOU, Nadine, DALIVOUST, Philippe, ARSENE, Olivier, MARQUES, Nathalie, PETIT, Thierry, MOLLON, Delphine, DAUBA, Jérôme, BONNIN, Nathalie, MORVAN, François, GARDNER, Miriam, MARTI, Adina, LEVACHE, Charles-Briac, LACHAIER, Emma, ACHILLE, Mihaela, VALMAR, Christophe, BOUAITA, Ryan, MEDIONI, Jacques, FOA, Cyril, DEL PIANO, Francesco, GOZY, Michel, ESCANDE, Anne, LEDUC, Nicolas, LUCAS, Brigitte, MILLE, Dominique, AMMARGUELLAT, Hanifa, NAJEM, Abeer, TROUBOUL, Fanny, BARTHELEMY, Philippe, DESCLOS, Hervé, MAYEUR, Didier, LORCHEL, Fabrice, GUINET, François, LAURENTY, Anne-Pascale, BOUDRANT, Axelle, GISSEROT, Olivier, ALLEAUME, Corinne, DE GRAMONT, Aimery, Bidard, François-Clément, Hardy-Bessard, Anne-Claire, Dalenc, Florence, Bachelot, Thomas, Pierga, Jean-Yves, de la Motte Rouge, Thibault, Sabatier, Renaud, Dubot, Coraline, Frenel, Jean-Sébastien, Ferrero, Jean Marc, Ladoire, Sylvain, Levy, Christelle, Mouret-Reynier, Marie-Ange, Lortholary, Alain, Grenier, Julien, Chakiba, Camille, Stefani, Laetitia, Plaza, Jérôme Edouard, Clatot, Florian, Teixeira, Luis, D'Hondt, Véronique, Vegas, Hélène, Derbel, Olfa, Garnier-Tixidre, Claire, Canon, Jean-Luc, Pistilli, Barbara, André, Fabrice, Arnould, Laurent, Pradines, Anne, Bièche, Ivan, Callens, Céline, Lemonnier, Jérôme, Berger, Frédérique, and Delaloge, Suzette

Published
2022
Full Text
View/download PDF

5. Impact of body mass index on overall survival in patients with metastatic breast cancer

Author

Saleh, Khalil, Carton, Matthieu, Dieras, Véronique, Heudel, Pierre-Etienne, Brain, Etienne, D’Hondt, Véronique, Mailliez, Audrey, Patsouris, Anne, Mouret-Reynier, Marie-Ange, Goncalves, Anthony, Ferrero, Jean Marc, Petit, Thierry, Emile, George, Uwer, Lionel, Debled, Marc, Dalenc, Florence, Jouannaud, Christelle, Ladoire, Sylvain, Leheurteur, Marianne, Cottu, Paul, Veron, Lucie, Savignoni, Alexia, Courtinard, Coralie, Robain, Mathieu, Delaloge, Suzette, and Deluche, Elise

Published
2021
Full Text
View/download PDF

6. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Author

Oaknin, A, Gladieff, L, Martínez-García, J, Villacampa, G, Takekuma, M, De Giorgi, U, Lindemann, K, Woelber, L, Colombo, N, Duska, L, Leary, A, Godoy-Ortiz, A, Nishio, S, Angelergues, A, Rubio, M, Fariñas-Madrid, L, Yamaguchi, S, Lorusso, D, Ray-Coquard, I, Manso, L, Joly, F, Alarcón, J, Follana, P, Romero, I, Lebreton, C, Pérez-Fidalgo, J, Yunokawa, M, Dahlstrand, H, D'Hondt, V, Randall, L, Oaknin, Ana, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, Takekuma, Munetaka, De Giorgi, Ugo, Lindemann, Kristina, Woelber, Linn, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Nishio, Shin, Angelergues, Antoine, Rubio, Maria Jesús, Fariñas-Madrid, Lorena, Yamaguchi, Satoshi, Lorusso, Domenica, Ray-Coquard, Isabelle, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Romero, Ignacio, Lebreton, Coriolan, Pérez-Fidalgo, J Alejandro, Yunokawa, Mayu, Dahlstrand, Hanna, D'Hondt, Véronique, Randall, Leslie M, Oaknin, A, Gladieff, L, Martínez-García, J, Villacampa, G, Takekuma, M, De Giorgi, U, Lindemann, K, Woelber, L, Colombo, N, Duska, L, Leary, A, Godoy-Ortiz, A, Nishio, S, Angelergues, A, Rubio, M, Fariñas-Madrid, L, Yamaguchi, S, Lorusso, D, Ray-Coquard, I, Manso, L, Joly, F, Alarcón, J, Follana, P, Romero, I, Lebreton, C, Pérez-Fidalgo, J, Yunokawa, M, Dahlstrand, H, D'Hondt, V, Randall, L, Oaknin, Ana, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, Takekuma, Munetaka, De Giorgi, Ugo, Lindemann, Kristina, Woelber, Linn, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Nishio, Shin, Angelergues, Antoine, Rubio, Maria Jesús, Fariñas-Madrid, Lorena, Yamaguchi, Satoshi, Lorusso, Domenica, Ray-Coquard, Isabelle, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Romero, Ignacio, Lebreton, Coriolan, Pérez-Fidalgo, J Alejandro, Yunokawa, Mayu, Dahlstrand, Hanna, D'Hondt, Véronique, and Randall, Leslie M

Abstract

Background: The GOG240 trial established bevacizumab with chemotherapy as standard first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial (ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030), we aimed to evaluate the addition of an immune checkpoint inhibitor to this standard backbone. Methods: In this investigator-initiated, randomised, open-label, phase 3 trial, patients from 92 sites in Europe, Japan, and the USA with metastatic (stage IVB), persistent, or recurrent cervical cancer that was measurable, previously untreated, and not amenable to curative surgery or radiation were randomly assigned 1:1 to receive standard therapy (cisplatin 50 mg/m2 or carboplatin area under the curve of 5, paclitaxel 175 mg/m2, and bevacizumab 15 mg/kg, all on day 1 of every 3-week cycle) with or without atezolizumab 1200 mg. Treatment was continued until disease progression, unacceptable toxicity, patient withdrawal, or death. Stratification factors were previous concomitant chemoradiation (yes vs no), histology (squamous cell carcinoma vs adenocarcinoma including adenosquamous carcinoma), and platinum backbone (cisplatin vs carboplatin). Dual primary endpoints were investigator-assessed progression-free survival according to Response Evaluation Criteria in Solid Tumours version 1.1 and overall survival analysed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT03556839, and is ongoing. Findings: Between Oct 8, 2018, and Aug 20, 2021, 410 of 519 patients assessed for eligibility were enrolled. Median progression-free survival was 13·7 months (95% CI 12·3–16·6) with atezolizumab and 10·4 months (9·7–11·7) with standard therapy (hazard ratio [HR]=0·62 [95% CI 0·49–0·78]; p<0·0001); at the interim overall survival analysis, median overall survival was 32·1 months (95% CI 25·3–36·8) versus 22·8 months (20·3–28·0), respectively (HR 0·68 [95% CI 0·52–0·88]; p=0·0046). Grade 3 or worse adverse events occurred in 79% of patient

Published
2024

7. Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohort

Author

Frank, Sophie, Carton, Matthieu, Dubot, Coraline, Campone, Mario, Pistilli, Barbara, Dalenc, Florence, Mailliez, Audrey, Levy, Christelle, D’Hondt, Véronique, Debled, Marc, Vermeulin, Thomas, Coudert, Bruno, Perrin, Christophe, Gonçalves, Anthony, Uwer, Lionel, Ferrero, Jean-Marc, Eymard, Jean-Christophe, Petit, Thierry, Mouret-Reynier, Marie-Ange, Patsouris, Anne, Guesmia, Tahar, Bachelot, Thomas, Robain, Mathieu, and Cottu, Paul

Published
2020
Full Text
View/download PDF

8. First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof‐of‐concept study

Author

Bardol, Thomas, primary, Eslami‐S, Zahra, additional, Masmoudi, Doryan, additional, Alexandre, Marie, additional, Duboys de Labarre, Marie, additional, Bobrie, Angélique, additional, D'Hondt, Véronique, additional, Guiu, Séverine, additional, Kurma, Keerthi, additional, Cayrefourcq, Laure, additional, Jacot, William, additional, and Alix‐Panabières, Catherine, additional

Published
2023
Full Text
View/download PDF

11. Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer

Author

Vendrell, Julie A., primary, Ban, Iulian O., additional, Solassol, Isabelle, additional, Audran, Patricia, additional, Cabello-Aguilar, Simon, additional, Topart, Delphine, additional, Lindet-Bourgeois, Clothilde, additional, Colombo, Pierre-Emmanuel, additional, Legouffe, Eric, additional, D’Hondt, Véronique, additional, Fabbro, Michel, additional, and Solassol, Jérôme, additional

Published
2023
Full Text
View/download PDF

12. First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof-of-concept study.

Author

Bardol, Thomas, Eslami-S, Zahra, Masmoudi, Doryan, Alexandre, Marie, Duboys de Labarre, Marie, Bobrie, Angélique, D'Hondt, Véronique, Guiu, Séverine, Kurma, Keerthi, Cayrefourcq, Laure, Jacot, William, and Alix-Panabières, Catherine

Subjects
METASTATIC breast cancer, CANCER patients, CLINICAL trials monitoring, PROOF of concept, PROTEIN-tyrosine kinases, KINASES, CANCER cell growth
Abstract

Background: For several years, the AXL tyrosine kinase receptor, a member of the Tyro3-Axl-Mer (TAM) family, has been considered a new strategic target in oncology. AXL overexpression is common in solid tumors and is associated with poor prognosis. In this context, the detection of a subset of circulating tumor cells (CTCs) that express AXL (AXL+ CTCs) could be clinically relevant. Methods: Immunostaining was performed to assess AXL expression in human breast cancer cell lines. The optimal conditions were established using flow cytometry. Spiking experiments were carried out to optimize the parameters of the CellSearch® system detection test. CTC enumeration and AXL expression were evaluated in patients with metastatic breast cancer (mBC) before treatment initiation. Results: An innovative AXL+ CTC detection assay to be used with the CellSearch® system was developed. In a prospective longitudinal clinical trial, blood samples from 60 patients with untreated mBC were analyzed to detect AXL+ CTCs with this new assay. CTCs were detected in 35/60 patients (58.3%) and AXL+ CTCs were identified in 7 of these 35 patients (11.7% of all patients). Conclusion: This newly established AXL+ CTC assay is a promising tool that can be used for liquid biopsy in future clinical trials to stratify and monitor patients with cancer receiving anti-AXL therapies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Author

Oaknin, Ana, Gladieff, Laurence, Martínez-García, Jerónimo, Villacampa, Guillermo, Takekuma, Munetaka, De Giorgi, Ugo, Lindemann, Kristina, Woelber, Linn, Colombo, Nicoletta, Duska, Linda, Leary, Alexandra, Godoy-Ortiz, Ana, Nishio, Shin, Angelergues, Antoine, Rubio, Maria Jesús, Fariñas-Madrid, Lorena, Yamaguchi, Satoshi, Lorusso, Domenica, Ray-Coquard, Isabelle, Manso, Luis, Joly, Florence, Alarcón, Jesús, Follana, Philippe, Romero, Ignacio, Lebreton, Coriolan, Pérez-Fidalgo, J Alejandro, Yunokawa, Mayu, Dahlstrand, Hanna, D'Hondt, Véronique, Randall, Leslie M, Abadie-Lacourtoisie, Sophie, Andreetta, Claudia, Anzizar, Nerea, Aoki, Daiseuke, Barretina-Ginesta, Maria-Pilar, Battista, Marco, Bellier, Charlotte, Bentzen, Anne Gry, Berton, Dominique, Billemont, Bertrand, Bjørge, Line, Bjurberg, Maria, Black, Destin, Bologna, Alessandra, Braicu, Elena Ioana, Casanova, Claudia, Chekerov, Radoslav, Chevalier, Annick, Cueva, Juan Fernando, Czogalla, Bastian, Delanoy, Nicolas, Denschlag, Dominik, Derke, Oscar, Eichbaum, Michael, Enomoto, Takayuki, Esteban, Carmen, Fabbro, Michel, Fehm, Tanja, Ferrero, Annamaria, Fleisch, Markus, Floquet, Anne, Frassoldati, Antonio, Gaba, Lydia, Gadducci, Angiolo, García, Yolanda, Geuna, Elena, Guerra, Eva, Hanker, Lars, Hardy-Bessard, Anne-Claire, Harter, Philipp, Hasegawa, Kosei, Hellman, Kristina, Herrero, Ana, Hilpert, Felix, Katsaros, Dionyssios, Koegel, Matthias, Koliadi, Anthoula, Kurtz, Jean-Emmanuel, Lampe, Bjoern, Lissoni, Andrea Alberto, Lortholary, Alain, Mangili, Giorgia, Mansi, Laura, Marmé, Frederik, Mathews, Cara, Mina, William, Minobe, Shinichiro, Moxley, Katherine, Nagao, Shoji, Nicoletto, Ornella, Nishino, Koji, Nishio, Hiroshi, Nishio, Shin, Oaknin, Ana, Onstad, Michaela, Pardo, Beatriz, Pérez-Fidalgo, J Alejandro, Pisano, Carmela, Poveda, Andrés, Radosa, Julia, Randall, Leslie M., Ray-Coquard, Isabelle, Redondo, Andrés, Richardson, Debra, Romero, Ignacio, Ronzino, Graziana, Rubio, Maria Jesús, Selle, Frederic, Takekuma, Munetaka, Takeshima, Nobuhiro, Tasca, Giulia, Tewari, Krishnansu, Todo, Yukiharu, Valabrega, Giorgio, Wimberger, Pauline, Woelber, Linn, Yamaguchi, Satoshi, You, Benoît, and Yunokawa, Mayu

Abstract

The GOG240 trial established bevacizumab with chemotherapy as standard first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial (ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030), we aimed to evaluate the addition of an immune checkpoint inhibitor to this standard backbone.

Published
2024
Full Text
View/download PDF

15. 2022-RA-579-ESGO A phase II study assessing safety and efficacy of cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure (CABOCOL study)

Author

Coquan, Elodie, primary, Lequesne, Justine, additional, Colomba, Emeline, additional, Frenel, Jean-Sébastien, additional, Abdeddaim, Cyril, additional, D’Hondt, Véronique, additional, Castera, Marie, additional, Abadie-Lacourtoisie, Sophie, additional, Dubot, Coraline, additional, Brachet, Pierre-Emmanuel, additional, Leconte, Alexandra, additional, Clarisse, Bénédicte, additional, and Joly, Florence, additional

Published
2022
Full Text
View/download PDF

16. Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France

Author

de Calbiac, Ombline, primary, Lusque, Amélie, additional, Mailliez, Audrey, additional, Bachelot, Thomas, additional, Uwer, Lionel, additional, Mouret-Reynier, Marie-Ange, additional, Emile, George, additional, Jouannaud, Christelle, additional, Gonçalves, Anthony, additional, Patsouris, Anne, additional, Diéras, Véronique, additional, Leheurteur, Marianne, additional, Petit, Thierry, additional, Cottu, Paul, additional, Ferrero, Jean-Marc, additional, D'Hondt, Véronique, additional, Desmoulins, Isabelle, additional, Mourato-Ribeiro, Joana, additional, Martin, Anne-Laure, additional, and Frenel, Jean-Sébastien, additional

Published
2022
Full Text
View/download PDF

18. Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer.

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre de génétique médicale UCL, Delaloge, Suzette, Dureau, Sylvain, D'Hondt, Véronique, Desmoulins, Isabelle, Heudel, Pierre-Etienne, Duhoux, Francois P, Levy, Christelle, Lerebours, Florence, Mouret-Reynier, Marie A, Dalenc, Florence, Frenel, Jean-Sébastien, Jouannaud, Christelle, Venat-Bouvet, Laurence, Nguyen, Suzanne, Callens, Cécile, Gentien, David, Rapinat, Audrey, Manduzio, Helene, Vincent-Salomon, Anne, Lemonnier, Jérôme, Cottu, Paul, French Breast cancer Intergroup Unicancer-UCBG, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre de génétique médicale UCL, Delaloge, Suzette, Dureau, Sylvain, D'Hondt, Véronique, Desmoulins, Isabelle, Heudel, Pierre-Etienne, Duhoux, Francois P, Levy, Christelle, Lerebours, Florence, Mouret-Reynier, Marie A, Dalenc, Florence, Frenel, Jean-Sébastien, Jouannaud, Christelle, Venat-Bouvet, Laurence, Nguyen, Suzanne, Callens, Cécile, Gentien, David, Rapinat, Audrey, Manduzio, Helene, Vincent-Salomon, Anne, Lemonnier, Jérôme, Cottu, Paul, and French Breast cancer Intergroup Unicancer-UCBG

Abstract

Besides their development as additional adjuvant treatments, CDK4/6 inhibitors combined with endocrine therapy could represent less toxic alternatives to chemotherapy in postmenopausal women with high-risk oestrogen receptor-positive, HER2-negative breast cancer currently a candidate for chemotherapy. The multicentre, international, randomised phase 2 NEOPAL trial showed that the letrozole-palbociclib combination led to clinical and pathological responses equivalent to sequential anthracycline-taxanes chemotherapy. Secondary objectives included survival outcomes. Secondary end-points of NEOPAL included progression-free survival (PFS) and invasive-disease free survival (iDFS) in the intent-to-treat population. Exploratory end-points were overall survival (OS) and breast cancer specific survival (BCSS) in the intent-to-treat population, as well as iDFS, OS and BCSS according to the administration of chemotherapy. Hundred and six patients were randomised. Pathological complete response rates were 3.8% and 5.9%. Twenty-three of the 53 patients in the letrozole-palbociclib arm received postoperative adjuvant chemotherapy. At a median follow-up of 40.4 months [0-56.6], 11 progressions have been observed, of which three were in the letrozole-palbociclib and 8 in the control arm. PFS (HR = 1.01; [95%CI 0.36-2.90], p = 0.98) and iDFS (HR = 0.83; [95%CI 0.31-2.23], p = 0.71) did not differ between both arms. The 40 months PFS rate was 86.7% [95%CI 78.0-96.4] and 89.9% [95%CI 81.8-98.7] in letrozole-palbociclib and control arms, respectively. Outcomes of patients who did not receive chemotherapy were not statistically different from those who received it. NEOPAL suggests that a neoadjuvant letrozole-palbociclib strategy may allow sparing chemotherapy in some patients with luminal breast cancer while allowing good long-term outcomes. Larger confirmatory studies are needed.

Published
2022

19. Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer

Author

Delaloge, Suzette, primary, Dureau, Sylvain, additional, D'Hondt, Véronique, additional, Desmoulins, Isabelle, additional, Heudel, Pierre-Etienne, additional, Duhoux, Francois P., additional, Levy, Christelle, additional, Lerebours, Florence, additional, Mouret-Reynier, Marie A., additional, Dalenc, Florence, additional, Frenel, Jean-Sébastien, additional, Jouannaud, Christelle, additional, Venat-Bouvet, Laurence, additional, Nguyen, Suzanne, additional, Callens, Cécile, additional, Gentien, David, additional, Rapinat, Audrey, additional, Manduzio, Helene, additional, Vincent-Salomon, Anne, additional, Lemonnier, Jérôme, additional, and Cottu, Paul, additional

Published
2022
Full Text
View/download PDF

20. Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study

Author

Falandry, Claire, primary, Pommeret, Fanny, additional, Gladieff, Laurence, additional, Tinquaut, Fabien, additional, Lorusso, Domenica, additional, Mouret-Reynier, Marie-Ange, additional, D'Hondt, Véronique, additional, Mollon-Grange, Delphine, additional, Floquet, Anne, additional, Abadie-Lacourtoisie, Sophie, additional, Brachet, Pierre-Emmanuel, additional, Stefani, Laetitia, additional, Rousseau, Frédérique, additional, Frenel, Jean-Sébastien, additional, Del Piano, Francesco, additional, Komulainen, Marja, additional, Warkus, Thomas, additional, Trédan, Olivier, additional, Pujade-Lauraine, Eric, additional, and Freyer, Gilles, additional

Published
2022
Full Text
View/download PDF

21. A Phase II Multicenter Trial on High-Dose Vitamin D Supplementation for the Correction of Vitamin D Insufficiency in Patients with Breast Cancer Receiving Adjuvant Chemotherapy

Author

Chartron, Elodie, primary, Firmin, Nelly, additional, Touraine, Célia, additional, Chapelle, Angélique, additional, Legouffe, Eric, additional, Rifai, Lobna, additional, Pouderoux, Stéphane, additional, Roca, Lise, additional, D’Hondt, Véronique, additional, and Jacot, William, additional

Published
2021
Full Text
View/download PDF

23. Additional file 1 of Changes in vitamin D and calcium metabolism markers in patients undergoing adjuvant chemotherapy for breast cancer

Author

Viala, Marie, Firmin, Nelly, Touraine, Célia, Pouderoux, Stéphane, Metge, Manon, Rifai, Lobna, Romieu, Gilles, de Forges, Hélène, Roca, Lise, Guiu, Séverine, D’Hondt, Véronique, and Jacot, William

Subjects
sense organs, skin and connective tissue diseases
Abstract

Additional file 1: Figure S1. Vitamin D serum level changes during the six chemotherapy cycles in patients with baseline vitamin D sufficient (n = 16) and insufficient concentration (n = 66). Table S1. Vitamin D level changes during the six cycles of chemotherapy in patients with baseline sufficient and insufficient vitamin D concentration.

Published
2021
Full Text
View/download PDF

26. Abstract PS12-03: Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment in luminal breast cancer: Survival results of the UNICANCER-NeoPAL study

Author

Delaloge, Suzette, primary, Dureau, Sylvain, additional, D'Hondt, Véronique, additional, Desmoulins, Isabelle, additional, Heudel, Pierre-Etienne, additional, Duhoux, François, additional, Levy, Christelle, additional, Lerebours, Florence, additional, Mouret-Reynier, Marie Ange, additional, Dalenc, Florence, additional, Frenel, Jean-Sébastien, additional, Jouannaud, Christelle, additional, Venat-Bouvet, Laurence, additional, Nguyen, Suzanne, additional, Callens, Cécile, additional, Gentien, David, additional, Lemonnier, Jerome, additional, Vincent-Salomon, Anne, additional, Manduzio, Hélène, additional, and Cottu, Paul-Henri, additional

Published
2021
Full Text
View/download PDF

27. Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program

Author

Bertho, Marion, primary, Fraisse, Julien, additional, Patsouris, Anne, additional, Cottu, Paul, additional, Arnedos, Monica, additional, Pérol, David, additional, Jaffré, Anne, additional, Goncalves, Anthony, additional, Lebitasy, Marie-Paule, additional, D’Hondt, Véronique, additional, Dalenc, Florence, additional, Ferrero, Jean-Marc, additional, Levy, Christelle, additional, Dabakuyo, Sandrine, additional, Rouzier, Roman, additional, Penault-Llorca, Frédérique, additional, Uwer, Lionel, additional, Eymard, Jean-Christophe, additional, Breton, Mathias, additional, Chevrot, Michaël, additional, Thureau, Sébastien, additional, Petit, Thierry, additional, Simon, Gaëtane, additional, and Frénel, Jean-Sébastien, additional

Published
2021
Full Text
View/download PDF

29. Brief Hospital Supervision of Exercise and Diet During Adjuvant Breast Cancer Therapy Is Not Enough to Relieve Fatigue: A Multicenter Randomized Controlled Trial

Author

Jacot, William, primary, Arnaud, Antoine, additional, Jarlier, Marta, additional, Lefeuvre-Plesse, Claudia, additional, Dalivoust, Philippe, additional, Senesse, Pierre, additional, Azzedine, Ahmed, additional, Tredan, Olivier, additional, Sadot-Lebouvier, Sophie, additional, Mas, Sébastien, additional, Carayol, Marion, additional, Bleuse, Jean-Pierre, additional, Gourgou, Sophie, additional, Janiszewski, Chloé, additional, Launay, Silene, additional, D’Hondt, Véronique, additional, Lauridant, Géraldine, additional, Grenier, Julien, additional, Romieu, Gilles, additional, Ninot, Gregory, additional, and Vanlemmens, Laurence, additional

Published
2020
Full Text
View/download PDF

30. Conditional Probability of Survival and Prognostic Factors in Long-Term Survivors of High-Grade Serous Ovarian Cancer

Author

Fabbro, Michel, primary, Colombo, Pierre-Emmanuel, additional, Leaha, Cristina Marinella, additional, Rouanet, Philippe, additional, Carrère, Sébastien, additional, Quenet, François, additional, Gutowski, Marian, additional, Mourregot, Anne, additional, D’Hondt, Véronique, additional, Coupier, Isabelle, additional, Vendrell, Julie, additional, Vilquin, Paul, additional, Pujol, Pascal, additional, Solassol, Jérôme, additional, and Mollevi, Caroline, additional

Published
2020
Full Text
View/download PDF

31. Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer

Author

Jacot, William, primary, Mazel, Martine, additional, Mollevi, Caroline, additional, Pouderoux, Stéphane, additional, D’Hondt, Véronique, additional, Cayrefourcq, Laure, additional, Bourgier, Céline, additional, Boissiere-Michot, Florence, additional, Berrabah, Fella, additional, Lopez-Crapez, Evelyne, additional, Bidard, François-Clément, additional, Viala, Marie, additional, Maudelonde, Thierry, additional, Guiu, Séverine, additional, and Alix-Panabières, Catherine, additional

Published
2020
Full Text
View/download PDF

32. Abstract P5-11-22: Clinical and biological efficacy of first line AI and palbociclib in ER+ HER2- MBC with detectable circulatingESR1mutation prior to treatment initiation

Author

Bidard, François-Clément, primary, Callens, Céline, additional, Dalenc, Florence, additional, Pistilli, Barbara, additional, de la Motte Rouge, Thibault, additional, Clatot, Florian, additional, D'Hondt, Véronique, additional, Teixeira, Luis, additional, Everhard, Sibille, additional, Vegas, Hélène, additional, Lemonnier, Jérôme, additional, Bieche, Ivan, additional, Pradines, Anne, additional, Paitel, Jean-François, additional, Spaeth, Dominique, additional, Canon, Jean-Luc, additional, Moullet, Isabelle, additional, Pierga, Jean-Yves, additional, Berger, Frédérique, additional, Bachelot, Thomas, additional, and Delaloge, Suzette, additional

Published
2020
Full Text
View/download PDF

33. Abstract P2-19-01: Impact of bone-only metastatic breast cancer on outcome in a real-life setting: A comprehensive analysis of 5,041 women from the ESME database

Author

Bertho, Marion, primary, Fraisse, Julien, additional, Patsouris, Anne, additional, Cottu, Paul, additional, Delaloge, Suzette, additional, Pérol, David, additional, Jaffré, Anne, additional, Goncalves, Anthony, additional, Lebitasy, Marie-Paule, additional, D'Hondt, Véronique, additional, Dalenc, Florence, additional, Ferrero, Jean-Marc, additional, Levy, Christelle, additional, Arveux, Patrick, additional, Rouzier, Roman, additional, Penault-Llorca, Frédérique, additional, Uwer, Lionel, additional, Eymard, Jean-Christophe, additional, Breton, Mathias, additional, Chevrot, Michaël, additional, Leheurteur, Marianne, additional, Velten, Michel, additional, Simon, Gaëtane, additional, and Frenel, Jean-Sébastien, additional

Published
2020
Full Text
View/download PDF

35. Phase III randomized study comparing 5 or 10 μg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies

Author

André, Marc, Baudoux, Etienne, Bron, Dominique, Canon, Jean-Luc, DʼHondt, Véronique, Fassotte, Marie-France, DʼHondt, Lionel, Fillet, Georges, Humblet, Yves, Jerusalem, Guy, Vermeulen, Philippe, Symann, Michel, and Beguin, Yves

Published
2003

37. UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2–positive subgroup

Author

D'Hondt, Véronique, primary, Canon, Jean-Luc, additional, Roca, Lise, additional, Levy, Christelle, additional, Pierga, Jean-Yves, additional, Le Du, Fanny, additional, Campone, Mario, additional, Desmoulins, Isabelle, additional, Goncalves, Anthony, additional, Debled, Marc, additional, Rios, Maria, additional, Ferrero, Jean-Marc, additional, Serin, Daniel, additional, Hardy-Bessard, Anne-Claire, additional, Piot, Gilles, additional, Brain, Etienne, additional, Dohollou, Nadine, additional, Orfeuvre, Hubert, additional, Lemonnier, Jerome, additional, Roché, Henri, additional, Delaloge, Suzette, additional, and Dalenc, Florence, additional

Published
2019
Full Text
View/download PDF

38. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer.

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer, Cottu, Paul, D'Hondt, Véronique, Dureau, Sylvain, Lerebours, Florence, Desmoulins, Isabelle, Heudel, Pierre-Etienne, Duhoux, François, Levy, Christelle, Mouret-Reynier, Marie-Ange, Dalenc, Florence, Frenel, Jean-Sébastien, Jouannaud, Christelle, Venat-Bouvet, Laurence, Nguyen, Suzanne, Ferrero, Jean-Marc, Canon, Jean-Luc, Grenier, Julien, Callens, Céline, Gentien, David, Lemonnier, Jérôme, Vincent-Salomon, Anne, Delaloge, Suzette, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer, Cottu, Paul, D'Hondt, Véronique, Dureau, Sylvain, Lerebours, Florence, Desmoulins, Isabelle, Heudel, Pierre-Etienne, Duhoux, François, Levy, Christelle, Mouret-Reynier, Marie-Ange, Dalenc, Florence, Frenel, Jean-Sébastien, Jouannaud, Christelle, Venat-Bouvet, Laurence, Nguyen, Suzanne, Ferrero, Jean-Marc, Canon, Jean-Luc, Grenier, Julien, Callens, Céline, Gentien, David, Lemonnier, Jérôme, Vincent-Salomon, Anne, and Delaloge, Suzette

Abstract

BACKGROUND: Palbociclib is a CDK4/6 inhibitor with demonstrated efficacy and safety in combination with endocrine therapy in advanced luminal breast cancer (LBC). We evaluated the respective efficacy and safety of chemotherapy and letrozole-palbociclib (LETPAL) combination as neoadjuvant treatment in patients with high-risk LBC. PATIENTS AND METHODS: NeoPAL (UCBG10/4, NCT02400567) is a randomised, parallel, non-comparative phase II study. Patients with ER-positive, HER2-negative, Prosigna®-defined luminal B, or luminal A and node-positive, stage II-III breast cancer, not candidate for breast-conserving surgery, were randomly assigned to either letrozole (2.5 mg daily) and palbociclib (125 mg daily, 3 weeks/4) during 19 weeks, or to FEC100 (5FU 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2)×3 21-day courses followed by docetaxel 100 mg/m2×3 21-day courses. Primary end point was residual cancer burden (RCB 0-I rate). Secondary end points included clinical response, proliferation-based markers, and safety. RESULTS: Overall, 106 patients were randomised [median Prosigna® ROR Score 71 (22-93)]. RCB 0-I was observed in four and eight patients in LETPAL [7.7% (95% CI 0.4-14.9)] and chemotherapy [15.7% (95% CI 5.7-25.7)] arms, respectively. Pathological complete response rates were 3.8% and 5.9%. Clinical response (75%) and breast-conserving surgery rates (69%) were similar in both arms. Preoperative Endocrine Prognostic Index 0 scores (breast cancer-specific survival) were observed in 17.6% and 8.0% of patients in LETPAL and chemotherapy arms, respectively. Safety profile was as expected, with 2 versus 17 serious adverse events (including 11 grade 4 serious AEs in the chemotherapy arm). CONCLUSION: LETPAL combination was associated with poor pathological response but encouraging clinical and biomarker responses in Prosigna®-defined high-risk LBC. Contemporary chemotherapy regimen was associated with poor pathological and biomarker responses, with a much less

Published
2018

39. Prise en charge du cancer du col de l’utérus métastatique et/ou en rechute

Author

Kurtz, Jean-Emmanuel, D’Hondt, Véronique, Lecuru, Fabrice, Lhomme, Catherine, Les Hôpitaux Universitaires de Strasbourg (HUS), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut du Cancer de Montpellier (ICM), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), and Institut Gustave Roussy (IGR)

Subjects
Treatment, Cancer du col de l’utérus, [SDV]Life Sciences [q-bio], Cervical cancer, Recurrent disease, Metastases, Rechute, Traitement, Métastases
Abstract

International audience; The prognosis of metastatic or recurrent cervical cancer remains dismal. The poor chemosensitivity of this tumor- is an issue, especially in case of recurrence in irradiated fields. Still, chemotherapy has shown some efficacy, and mostly consists in platinum-based doublets. The addition of bevacizumab to chemotherapy has been recently validated. However, most of these patients present with complex clinical situations and the treatment strategy has to be discussed in multidisciplinary tumor boards.; Le pronostic des cancers du col utérin d’emblée métastatiques ou récidivants est particulièrement péjoratif. Ces tumeurs sont peu chimio-sensibles, surtout si elles surviennent dans une zone préalablement irradiée. En cas d’indication de chimiothérapie, les protocoles proposés sont le plus souvent des doublets comportant du platine. L’indication de l’association de bévacizumab à ces protocoles de chimiothérapie représente le progrès le plus récent dans la prise en charge de cette affection. La complexité des présentations cliniques et de la stratégie de prise en charge requiert une discussion des dossiers au cas par cas, en réunion de concertation pluridisciplinaire.

Published
2017

40. Astroglial expression of the P-glycoprotein is controlled by intracellular CNTF

Author

Guillet Catherine, d'Hondt Véronique, Feyens Anne-Marie, Fages Christiane, Monville Christelle, Vernallis Ann, Gascan Hugues, and Peschanski Marc

Subjects
differentiation, IL-6-type cytokines, astrogliosis, multi-drug resistance, Cytology, QH573-671
Abstract

Abstract Background The P-glycoprotein (P-gp), an ATP binding cassette transmembrane transporter, is expressed by astrocytes in the adult brain, and is positively modulated during astrogliosis. In a search for factors involved in this modulation, P-gp overexpression was studied in long-term in vitro astroglial cultures. Results Surprisingly, most factors that are known to induce astroglial activation in astroglial cultures failed to increase P-gp expression. The only effective proteins were IFNγ and those belonging to the IL-6 family of cytokines (IL-6, LIF, CT-1 and CNTF). As well as P-gp expression, the IL-6 type cytokines - but not IFNγ - stimulated the expression of endogenous CNTF in astrocytes. In order to see whether an increased intracellular level of CNTF was necessary for induction of P-gp overexpression by IL-6 type cytokines, by the same cytokines analysis was carried out on astrocytes obtained from CNTF knockout mice. In these conditions, IFNγ produced increased P-gp expression, but no overexpression of P-gp was observed with either IL-6, LIF or CT-1, pointing to a role of CNTF in the intracellular signalling pathway leading to P-gp overexpression. In agreement with this suggestion, application of exogenous CNTF -which is internalised with its receptor - produced an overexpression of P-gp in CNTF-deficient astrocytes. Conclusions These results reveal two different pathways regulating P-gp expression and activity in reactive astrocytes, one of which depends upon the intracellular concentration of CNTF. This regulation of P-gp may be one of the long searched for physiological roles of CNTF.

Published
2002
Full Text
View/download PDF

41. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial

Author

Oza, Amit M, primary, Matulonis, Ursula A, additional, Malander, Susanne, additional, Hudgens, Stacie, additional, Sehouli, Jalid, additional, del Campo, Josep M, additional, Berton-Rigaud, Dominique, additional, Banerjee, Susana, additional, Scambia, Giovanni, additional, Berek, Jonathan S, additional, Lund, Bente, additional, Tinker, Anna V, additional, Hilpert, Felix, additional, Vázquez, Isabel Palacio, additional, D'Hondt, Véronique, additional, Benigno, Benedict, additional, Provencher, Diane, additional, Buscema, Joseph, additional, Agarwal, Shefali, additional, and Mirza, Mansoor R, additional

Published
2018
Full Text
View/download PDF

42. Abstract 4589: Expression of PD-L1 on circulating breast cancer cells: Correlation with clinicopathologic data and impact on prognosis

Author

Jacot, William, primary, Mazel, Martine, additional, Mollevi, Caroline, additional, Pouderoux, Stéphane, additional, D'Hondt, Véronique, additional, Cayrefourcq, Laure, additional, Ducteil, Angélique, additional, Viala, Marie, additional, Maudelonde, Thierry, additional, Guiu, Séverine, additional, and Alix-Panabières, Catherine, additional

Published
2018
Full Text
View/download PDF

45. Interval Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in First-Line Treatment for Advanced Ovarian Carcinoma: A Feasibility Study

Author

D’Hondt, Véronique, primary, Goffin, Frédéric, additional, Roca, Lise, additional, Dresse, Damien, additional, Leroy, Chantal, additional, Kerger, Joseph, additional, Cordier, Lionel, additional, de Forges, Hélène, additional, Veys, Isabelle, additional, and Liberale, Gabriel, additional

Published
2016
Full Text
View/download PDF

46. Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)

Author

UCL - Autre, Giuliani, Rosa, Durbecq, Virginie, Di Leo, Angelo, Paesmans, Marianne, Larsimont, Denis, Leroy, Jean-Yves, Borms, Marleen, Vindeuoghel, Anita, Jerusalem, Guy, D'Hondt, Véronique, Dirix, Luc, Canon, Jean-Luc, Richard, Vincent, Cocquyt, Veronique, Majois, Francoise, Reginster, Michel, Demol, Jan, Kains, Jean-Pierre, Delree, Paul, Keppens, Carine, Sotiriou, Christos, Piccart, Martine, Cardoso, Fatima, UCL - Autre, Giuliani, Rosa, Durbecq, Virginie, Di Leo, Angelo, Paesmans, Marianne, Larsimont, Denis, Leroy, Jean-Yves, Borms, Marleen, Vindeuoghel, Anita, Jerusalem, Guy, D'Hondt, Véronique, Dirix, Luc, Canon, Jean-Luc, Richard, Vincent, Cocquyt, Veronique, Majois, Francoise, Reginster, Michel, Demol, Jan, Kains, Jean-Pierre, Delree, Paul, Keppens, Carine, Sotiriou, Christos, Piccart, Martine, and Cardoso, Fatima

Abstract

Aim: Trastuzumab (T), a humanised monoclonal antibody against HER-2, is active in HER2-positive MBC patients. However, nearly 60% of the patients do not benefit from T, stressing the need for additional predictive markers. The following markers could be implicated in response to T. (1) the magnitude of Her-2 gene amplification; (2) the co-expression of the other HER family receptors, possibly responsible for HER-2 trans-activation; (3) the activated status of HER-2; (4) the activated status of downstream effectors as mitogen-activated protein kinases (MAPKs), p38 and p27. Methods: Medical files of patients with MBC treated with T either as a single agent or in combination with chemotherapy (CT) were reviewed. HER family members (EGFR, HER-2, HER-3, HER-4), the phosphorylated forms of EGFR (p-EGFR), HER-2 (p-HER-2) and of the downstream effectors were evaluated in the archival tumours. The correlation between clinical outcome and the expression of these markers was investigated. Results: (1) Increasing values of Her-2 amplification were associated with a higher probability of achieving an objective response; (2) no statistical significant correlation between the expression of the HER family receptors was found; (3) p-HER-2 was predictive of response in patients treated with T+CT; (4) a statistically significant correlation between p-ERK 1/2, p-p38 and p-HER-2 emerged, pointing to the activated vertical pathway p-HER-2 -> p-MAPKs. Conclusions: p-HER-2 and the magnitude of HeT-2 amplification were predictive of response to T and their role deserves to be analysed in larger and more homogenous T-treated populations such as those from large phase III trials. (c) 2006 Elsevier Ltd. All rights reserved.

Published
2007

47. Interval Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in First-Line Treatment for Advanced Ovarian Carcinoma.

Author

D'Hondt, Véronique, Goffin, Frédéric, Roca, Lise, Dresse, Damien, Leroy, Chantal, Kerger, Joseph, Cordier, Lionel, de Forges, Hélène, Veys, Isabelle, and Liberale, Gabriel

Abstract

Objectives: We conducted a phase 2 trial to assess the feasibility of interval cytoreductive surgery (CS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin in patients with stage III and IV pleural ovarian carcinoma in first-line treatment with no macroscopic residual disease after surgery. Methods: Patients could be treated either with primary CS with HIPEC followed by 6 conventional cycles of chemotherapy or with 3 or 4 cycles of neoadjuvant chemotherapy before CS with HIPEC and 3 postoperative chemotherapy cycles. Hyperthermic intraperitoneal chemotherapy was performed with cisplatin (50 mg/m2) for 60 minutes, only in case of complete cytoreduction. Results: Nineteen patients were included in the study, and they all underwent neoadjuvant chemotherapy before CS. Sixteen patients underwent complete CS with HIPEC. There was no mortality, and morbidity of CS with HIPEC was acceptable. The HIPEC procedure did not prevent the administration of the standard first-line treatment. In the 16 patients who underwent CS with HIPEC, the outcomes were very good. Conclusion: Our study shows an acceptable toxicity of adding HIPEC to the standard first-line treatment in patients with stage III ovarian carcinoma treated with interval CS. Further studies are needed to confirm the role of HIPEC in the treatment of ovarian carcinoma. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

48. Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies.

Author

Andr´, Marc, Baudoux, Etienne, Bron, Dominique, Canon, Jean-Luc, D'Hondt, Véronique, Fassotte, Marie-France, D'Hondt, Lionel, Fillet, Georges, Humblet, Yves, Jerusalem, Guy, Vermeulen, Philippe, Symann, Michel, Beguin, Yves, André, Marc, and D'Hondt, Véronique

Subjects
FILGRASTIM, TRANSPLANTATION of organs, tissues, etc., GROWTH factors
Abstract

Background: It is not known whether increasing the dose of filgrastim after mobilizing chemotherapy improves collection of peripheral blood progenitor cells (PBPC) and leads to faster hematopoietic engraftment after autologous transplantation.Study Design and Methods: A randomized, open-label, multicenter trial was carried out in patients with breast cancer, multiple myeloma, and lymphoma, in which patients were randomized to receive 5 or 10 microg per kg per day of filgrastim after standard chemotherapy to mobilize PBPCs. After high-dose chemotherapy, the components from the first two leukapheresis procedures were returned, and all patients received 5 microg per kg day of filgrastim after transplantation.Results: A total of 131 patients were randomized, of whom 128 were mobilized (Group A, 5 microg/kg, n = 66; Group B, 10 microg/kg, n = 62) and 112 were transplanted. Only six patients were not transplanted because of insufficient CD34+ cell numbers. The median number of CD34+ cells collected in the first two leukapheresis procedures tended to be higher in Group B than in Group A (12.0 vs. 7.2 x 10(6)/kg, NS), but after transplantation there was no significant difference in median times to platelet (9 days in both groups) or neutrophil (8 days in both groups) engraftment or the number of platelet transfusions (three in both groups). A subsequent subgroup analysis separating patients transplanted after first- or second-line chemotherapy also showed no measurable impact of filgrastim dose on the median CD34+ cell yield or on platelet engraftment in either subgroup.Conclusion: PBPC mobilization with chemotherapy and 5 microg per kg of filgrastim is very efficient, and 10 microg per kg of filgrastim does not provide additional clinical benefit. [ABSTRACT FROM AUTHOR]

Published
2003
Full Text
View/download PDF

49. Multifactorial Approach to Predicting Resistance to Anthracyclines

Author

Desmedt, Christine, primary, Di Leo, Angelo, additional, de Azambuja, Evandro, additional, Larsimont, Denis, additional, Haibe-Kains, Benjamin, additional, Selleslags, Jean, additional, Delaloge, Suzette, additional, Duhem, Caroline, additional, Kains, Jean-Pierre, additional, Carly, Birgit, additional, Maerevoet, Marie, additional, Vindevoghel, Anita, additional, Rouas, Ghislane, additional, Lallemand, Françoise, additional, Durbecq, Virginie, additional, Cardoso, Fatima, additional, Salgado, Roberto, additional, Rovere, Rodrigo, additional, Bontempi, Gianluca, additional, Michiels, Stefan, additional, Buyse, Marc, additional, Nogaret, Jean-Marie, additional, Qi, Yuan, additional, Symmans, Fraser, additional, Pusztai, Lajos, additional, D'Hondt, Véronique, additional, Piccart-Gebhart, Martine, additional, and Sotiriou, Christos, additional

Published
2011
Full Text
View/download PDF

50. Phase III randomized study comparing 5 or 10 microg per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies.

Author

UCL - Cliniques universitaires Saint-Luc, UCL - MD/MINT - Département de médecine interne, André, Marc, Humblet, Yves, Baudoux, Etienne, Bron, Dominique, Canon, Jean-Luc, Fassotte, Marie-France, Fillet, Georges, Jerusalem, Guy, Vermeulen, Philippe, Beguin, Yves, D'hondt, Véronique, Symann, Michel, UCL - Cliniques universitaires Saint-Luc, UCL - MD/MINT - Département de médecine interne, André, Marc, Humblet, Yves, Baudoux, Etienne, Bron, Dominique, Canon, Jean-Luc, Fassotte, Marie-France, Fillet, Georges, Jerusalem, Guy, Vermeulen, Philippe, Beguin, Yves, D'hondt, Véronique, and Symann, Michel

Abstract

BACKGROUND: It is not known whether increasing the dose of filgrastim after mobilizing chemotherapy improves collection of peripheral blood progenitor cells (PBPC) and leads to faster hematopoietic engraftment after autologous transplantation. STUDY DESIGN AND METHODS: A randomized, open-label, multicenter trial was carried out in patients with breast cancer, multiple myeloma, and lymphoma, in which patients were randomized to receive 5 or 10 microg per kg per day of filgrastim after standard chemotherapy to mobilize PBPCs. After high-dose chemotherapy, the components from the first two leukapheresis procedures were returned, and all patients received 5 microg per kg day of filgrastim after transplantation. RESULTS: A total of 131 patients were randomized, of whom 128 were mobilized (Group A, 5 microg/kg, n = 66; Group B, 10 microg/kg, n = 62) and 112 were transplanted. Only six patients were not transplanted because of insufficient CD34+ cell numbers. The median number of CD34+ cells collected in the first two leukapheresis procedures tended to be higher in Group B than in Group A (12.0 vs. 7.2 x 10(6)/kg, NS), but after transplantation there was no significant difference in median times to platelet (9 days in both groups) or neutrophil (8 days in both groups) engraftment or the number of platelet transfusions (three in both groups). A subsequent subgroup analysis separating patients transplanted after first- or second-line chemotherapy also showed no measurable impact of filgrastim dose on the median CD34+ cell yield or on platelet engraftment in either subgroup. CONCLUSION: PBPC mobilization with chemotherapy and 5 microg per kg of filgrastim is very efficient, and 10 microg per kg of filgrastim does not provide additional clinical benefit.

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results